巨噬细胞活化标志物可溶性CD163与胰岛素敏感性和β细胞功能纵向相关
在PROMISE研究中,408名2型糖尿病高危成人接受为期6年共3次评估,发现sCD163纵向与胰岛素敏感性及β细胞功能呈负相关,并与血糖异常发生风险升高相关,加入sCD163可改善血糖异常的预测。
要点
- sCD163升高与胰岛素敏感性和β细胞功能下降纵向相关。
- sCD163升高与血糖异常发生风险增加相关。
- sCD163加入临床模型可改善血糖异常预测。
核心结论
- sCD163纵向与2型糖尿病发病前的核心代谢异常相关。
研究设计与样本
- PROMISE前瞻性研究纳入408名2型糖尿病高危成人,6年内共3次评估。
主要发现
- sCD163每升高1个标准差,HOMA2-%S变化为-7.01%(95%CI -12.26至-1.44),ISI变化为-7.60%(95%CI -11.09至-3.97)。
- sCD163每升高1个标准差,ISSI-2变化为-4.67(95%CI -8.59至-0.58),IGI/HOMA-IR变化为-8.75(95%CI -15.42至-1.56)。
- sCD163升高与血糖异常发生风险相关,OR=1.04(95%CI 1.02-1.06,P<0.001)。
- 在临床变量模型中加入sCD163后,预测血糖异常的AROC从0.638提高到0.6731(P<0.05)。
临床怎么用
- sCD163可作为评估2型糖尿病高危人群代谢功能障碍的潜在炎症标志物。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Chronic inflammation arising from adipose tissue macrophage (ATM) activation may be central in type 2 diabetes etiology. Our objective was to assess the longitudinal associations of soluble CD163 (sCD163), a novel biomarker of ATM activation, with insulin sensitivity, β-cell function, and dysglycemia in high-risk subjects. METHODS: Adults at risk for type 2 diabetes in the Prospective Metabolism and Islet Cell Evaluation (PROMISE) study had 3 assessments over 6 years (n = 408). Levels of sCD163 were measured using fasting serum. Insulin sensitivity was assessed by HOMA2-%S and the Matsuda index (ISI). β-cell function was determined by insulinogenic index (IGI) over HOMA-IR and insulin secretion-sensitivity index-2 (ISSI-2). Incident dysglycemia was defined as the onset of impaired fasting glucose, impaired glucose tolerance, or type 2 diabetes. Generalized estimating equations (GEE) evaluated longitudinal associations of sCD163 with insulin sensitivity, β-cell function, and incident dysglycemia adjusting for demographic and lifestyle covariates. Areas under receiver-operating-characteristic curve (AROC) tested whether sCD163 improved dysglycemia prediction in a clinical model. RESULTS: Longitudinal analyses showed significant inverse associations between sCD163 and insulin sensitivity (% difference per standard deviation increase of sCD163 for HOMA2-%S (β = -7.01; 95% CI, -12.26 to -1.44) and ISI (β = -7.60; 95% CI, -11.09 to -3.97) and β-cell function (ISSI-2 (β = -4.67; 95 %CI, -8.59 to -0.58) and IGI/HOMA-IR (β = -8.75; 95% CI, -15.42 to -1.56)). Increased sCD163 was associated with greater risk for incident dysglycemia (odds ratio = 1.04; 95% CI, 1.02-1.06; P < 0.001). Adding sCD163 data to a model with clinical variables improved prediction of incident dysglycemia (AROC=0.6731 vs 0.638; P < 0.05). CONCLUSIONS: sCD163 was longitudinally associated with core disorders that precede the onset of type 2 diabetes.
引用
- Semnani-Azad Z, Connelly PW, Johnston LW, et al. The Macrophage Activation Marker Soluble CD163 is Longitudinally Associated With Insulin Sensitivity and β-cell Function. J Clin Endocrinol Metab. 2020. PMID: 31677389. doi:10.1210/clinem/dgz166
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。